Figure 4: MET fusions constitutively activate oncogenic signalling pathways and are inhibited by cabozantinib and PF-04217903. | Nature Communications

Figure 4: MET fusions constitutively activate oncogenic signalling pathways and are inhibited by cabozantinib and PF-04217903.

From: Activating MET kinase rearrangements in melanoma and Spitz tumours

Figure 4

(a) Melan-a cells (immortalized mouse melanocytes) were stably transduced with full-length MET, TRIM4-MET and ZKSCAN1-MET expression constructs. The expressed fusion proteins were detected with by an MET antibody at the predicted molecular weights of 79 and 65 kDa (longer exposure upper MET panel, shorter exposure lower MET panel). TRIM4-MET and ZKSCAN1-MET were phosphorylated at tyrosine 1,234/1,235 in the absence of serum. (b) Treatment with cabozantinib or PF-04217903 for 4 h (both at 100 nM) significantly decreased p-MET and downstream signalling.

Back to article page